)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
AIM ImmunoTech
AIM ImmunoTech (AIM) investor relations material
AIM ImmunoTech Corporate Connect Webinar Series summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Connect Webinar Series summary11 Feb, 2026
Strategic focus and clinical progress
Ampligen is being repurposed from chronic fatigue syndrome to oncology, with a primary focus on pancreatic cancer based on strong safety and efficacy data from multiple solid tumor studies in collaboration with major industry partners.
The pancreatic cancer program began in 2017 with Dutch government approval for an early access program, treating 57 late-stage patients and progressing to a phase II trial with AstraZeneca's Imfinzi at Erasmus Medical Center.
Ampligen's mechanism of action involves converting immunosilent (cold) tumors into immunoresponsive (hot) tumors by altering the tumor microenvironment, supported by specific immunological biomarkers.
The safety profile is robust, with over 100,000 IV doses administered and additional safety data from intranasal and intraperitoneal studies.
The company is prioritizing new drug approval for late-stage metastatic pancreatic cancer, addressing a significant unmet need.
Intellectual property and market exclusivity
Ampligen benefits from both patent and orphan drug designations, providing market exclusivity in the US and EU, with a recent US patent covering Ampligen plus PD-L1 valid until 2039.
Orphan drug exclusivity periods begin upon drug approval, offering up to 10 years of protection in the EU.
A Netherlands patent has also been granted for the Ampligen plus checkpoint inhibitor combination.
Clinical outcomes and data highlights
In the Dutch early access program, Ampligen extended median overall survival to 19.7 months versus 12.5 months for standard care, an 8.6-month benefit.
Patients reported significant improvements in quality of life, a critical factor in late-stage pancreatic cancer.
Biomarker analysis, including neutrophil-lymphocyte ratio and CA 19-9 levels, correlates with improved survival and progression-free survival.
Ongoing phase II DURIPANC trial interim results show positive safety, efficacy, and quality of life data, supporting advancement to phase III.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next AIM ImmunoTech earnings date
Q4 202531 Mar, 2026
AIM ImmunoTech
Next AIM ImmunoTech earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma, Inc., is an immuno-pharmaceutical company dedicated to the research and development of therapeutics for the treatment of multiple types of cancers, viral diseases, and immune-deficiency disorders. The company's leading product candidate is Ampligen, a drug composed of macromolecular ribonucleic acid molecules aimed at treating chronic fatigue syndrome (CFS). Ampligen is also under development for various cancer types, including renal cell carcinoma, malignant melanoma, and others, as well as for conditions like Hepatitis B, HIV, COVID-19, and post-COVID conditions. Another key product is Alferon N Injection, an injectable formulation of natural alpha interferon for treating human papillomavirus (HPV) and genital warts. The company is headquartered in Ocala, Florida, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage